CA
NZ
UK
AU
IND
US
Total revenue was $1,341.8 million, up 6.0% on both a reported and constant currency basis, from $1,265.3 million.Operating Incomerose 22.2% to $362.5 million, lifting theOperating Marginto 27.0% from 23.4%. Net income grew 24.4% to $261.8 million, or $2.08 per diluted share, against $210.5 million, …
Revenues were $114.3 million, up from $104.2 million a year earlier. For the nine months, revenues were $326.6 million, up 6.8% from $305.7 million.
Gross premiums written increased 17.3% to $819.7 million from $698.8 million, and net premiums earned rose 13.1% to $591.3 million.Net Incomeattributable to common shareholders was $81.5 million, or $0.81 per diluted share, compared with $136.2 million, or $1.32, a year earlier.
Net loss was $15.9 million, compared with $58.5 million a year earlier, and the loss attributable to common stockholders was $0.05 per share against $0.17. The improvement came mainly fromImpairmentcharges of $16.2 million, versus $104.4 million, and from interest expense that fell 14.8% to …
Total expenses rose to $52.8 million from $49.5 million, leaving net investment income at $87.3 million, or $0.47 per basic share, compared with $88.6 million, or $0.49. Distributions paid were $0.47 per share in both periods, so net investment income covered the payout on …
Product revenue was $946 million versus $927 million, while service and other revenue was $183 million versus $157 million, which is about 17% higher on a calculated basis. Chief Executive Jacob Thaysen pointed to healthy clinicalDemandand strong NovaSeq X placements as the drivers of …
Research and development expense was $20.7 million, up $9.9 million from $10.9 million a year earlier. Direct spending on atebimetinib was $13.6 million against $5.1 million, and the company attributed $8.5 million of the increase to running the MAPKeeper 301 trial.
Orders were the stronger number. Reported orders came in at $2,345 million, up 21%, with organic orders up 18%. Chairman and CEO Vicente Reynal described an improvedDemandenvironment, with healthy activity across geographies and end markets.
Net sales were $15,220 million, up from $12,604 million, an increase of 20.8% that came from growth in every region. Advanced Solutions rose 40%, Client and Endpoint Solutions rose 10%, Cloud-based Solutions rose 31% and Other services rose 35%. The 2025 sale of the …
Revenue was $265.1 million, up from $244.9 million in the second quarter and $240.0 million in the third quarter of 2025. On a calculated basis, that is growth of about 8.2% sequentially and 10.4% year over year.
Please wait processing your request...